Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder

被引：0
|
作者：
Greg W Mattingly
Richard H Weisler
Joel Young
Ben Adeyi
Bryan Dirks
Thomas Babcock
Robert Lasser
Brian Scheckner
David W Goodman
机构：
[1] St Charles Psychiatric Associates/Midwest Research,Duke University Medical Center
[2] 4801 Weldon Spring Pkwy,undefined
[3] Durham,undefined
[4] NC,undefined
[5] and University of North Carolina at Chapel Hill,undefined
[6] Rochester Center for Behavioral Medicine,undefined
[7] Shire Development LLC,undefined
[8] Formerly of Shire Development LLC,undefined
[9] Johns Hopkins University School of Medicine,undefined
来源：
BMC Psychiatry | / 13卷
关键词：
Lisdexamfetamine dimesylate (LDX); Attention-deficit/hyperactivity disorder (ADHD); Adults; Response; Remission;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Lisdexamfetamine dimesylate: a guide to its use in attention-deficit hyperactivity disorder
    Drugs & Therapy Perspectives, 2010, 26 (10) : 1 - 5
  • [22] A Long-Term Open-Label Safety and Effectiveness Trial of Lisdexamfetamine Dimesylate in Adolescents With Attention-Deficit/Hyperactivity Disorder
    Findling, Robert L.
    Cutler, Andrew J.
    Saylor, Keith
    Gasior, Maria
    Hamdani, Mohamed
    Ferreira-Cornwell, M. Celeste
    Childress, Ann C.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2013, 23 (01) : 11 - 21
  • [23] Long-term effectiveness and safety of lisdexamfetamine dimesylate in children aged 6-12 with attention-deficit/hyperactivity disorder
    McGough, J.
    Childress, A.
    Krishnan, S.
    Findling, R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S559 - S559
  • [24] Long-term safety and tolerability of lisdexamfetamine dimesylate in children aged 6 to 12 years with attention-deficit/hyperactivity disorder
    Findling, Robert L.
    Lopez, Frank A.
    Childress, Ann C.
    Krishnan, Suma
    McGough, James
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2007, 17 (06) : 875 - 875
  • [25] Maintenance of Efficacy of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder: Randomized Withdrawal Design
    Brams, Matthew
    Weisler, Richard
    Findling, Robert L.
    Gasior, Maria
    Hamdani, Mohamed
    Ferreira-Cornwell, M. Celeste
    Squires, Liza
    JOURNAL OF CLINICAL PSYCHIATRY, 2012, 73 (07) : 977 - 983
  • [26] Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in Europe
    Siffel, Csaba
    Page, Matthew
    Maxwell, Tricia
    Thun, Barbara
    Kolb, Nikolaus
    Rosenlund, Mats
    von Bredow, Dorothea
    Keja, Jacco
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2020, 30 (07) : 439 - 447
  • [27] EFFICACY OUTCOMES IN AGE AND SEX SUBGROUPS FROM TWO CLINICAL TRIALS OF LISDEXAMFETAMINE DIMESYLATE IN THE TREATMENT OF ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
    Adler, L. A.
    Dirks, B.
    Adeyi, B.
    Squires, L. A.
    EUROPEAN PSYCHIATRY, 2014, 29
  • [28] Lisdexamfetamine in the treatment of attention-deficit/hyperactivity disorder in adults
    Anthony L. Rostain
    Current Psychiatry Reports, 2009, 11 : 341 - 342
  • [29] Lisdexamfetamine DimesylateIn Attention-Deficit Hyperactivity Disorder in Adults
    Juliane Weber
    M. Asif A. Siddiqui
    CNS Drugs, 2009, 23 : 419 - 425
  • [30] Lisdexamfetamine in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults
    Rostain, Anthony L.
    CURRENT PSYCHIATRY REPORTS, 2009, 11 (05) : 341 - 342
12345